Company / Profit Margin
SAB Biotherapeutics, Inc. Profit Margin History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-2579.0%
FY2025
5-year range
-2579.0% / 36.4%
FY2021-FY2025
Trend
-36.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin has declined for 4 consecutive years, from 36.4% in FY2021 to -2579.0% in FY2025.
Based on SEC 10-K filings.
-2579.0% in FY2025 with a 3-year CAGR of -2550.9%.
Declined from -78.4% to -2579.0% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- -2550.9pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- SAB Biotherapeutics, Inc.'s profit margin has declined for 4 consecutive years.
- In FY2025, profit margin decreased 36.9% year-over-year.
- Peak profit margin was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -2579.0% | -36.9% |
| FY2024 | -1884.5% | -2303.7% |
| FY2023 | -78.4% | -178.4% |
| FY2022 | -28.2% | -177.3% |
| FY2021 | 36.4% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026